---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-034834"
form_type: "8-K"
ticker: "ICU"
cik: "0001831868"
company_name: "SeaStar Medical Holding Corp"
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:32:24.617944+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# SeaStar Medical Q3 revenue $0.2M, net loss $3.5M; QUELIMMUNE orders rising

## Summary
- Net revenue $0.2M (Q3 2024: $0.1M); net loss $3.5M ($0.13/sh) vs $4.5M ($1.10/sh) a year ago.
- Cash $13.8M at Sep 30, 2025, up from $1.8M at Dec 31, 2024; raised $12.4M in Q3 via equity and warrant exercise.
- Three top children's hospitals adopted QUELIMMUNE; Q4 orders to date exceed full Q3 orders.
- NEUTRALIZE-AKI trial interim analysis showed positive safety/efficacy signal; enrollment target raised to 339 patients (146 enrolled).
- QUELIMMUNE SAVE registry shows 76% 60-day and 71% 90-day survival in 21 pediatric AKI patients.

## SEC filing metadata
- accession: 0001437749-25-034834
- form_type: 8-K
- ticker: ICU
- cik: 0001831868
- company_name: SeaStar Medical Holding Corp
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831868/000143774925034834/0001437749-25-034834-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831868/000143774925034834/icu20250829_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-034834
- JSON: https://secwatch.observer/filing/0001437749-25-034834.json
- Plain text: https://secwatch.observer/filing/0001437749-25-034834.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.